Haleon

Haleon plc
Company type	Public limited company
Traded as	LSE: HLN; NYSE: HLN; FTSE 100 component;
ISIN	GB00BMX86B70
Industry	Healthcare; Consumer goods;
Predecessor	GSK Consumer Healthcare; Pfizer Consumer Healthcare
Founded	18 July 2022
Headquarters	Weybridge, Surrey, England
Area served	Worldwide
Key people	Dave Lewis (Chairman); Brian McNamara (CEO);
Products	Oral hygiene and medicines; nutritional products; over-the-counter medicines;
Brands	Actifed; Advil; Alinamin; Aquafresh; Beechams; Biotene; Caltrate; Centrum; ChapStick; Contac; Emergen-C; Eno; Excedrin; Fenbid; Fenistil; Flonase; Maclean; Nexium; Nicorette; Nicotinell; Odol; Otrivin; Panadol; Parodontax; Polident; Sensodyne; Theraflu; Tums; Voltaren;
Revenue	£10,858 million (2022)
Operating income	£1,825 million (2022)
Net income	£1,119 million (2022)
Total assets	£34,815 million (2022)
Total equity	£16,457 million (2022)
Number of employees	24,000 (2023)
Website	www.haleon.com

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including ChapStick lip balm, Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins. The company is a global leader in over the counter medicines with a 7.3 percent market share.

Haleon was established on 18 July 2022 as a corporate spin-off from GSK.

Sir David Lewis is chairman, with Brian McNamara as CEO. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.